SynthesisSystematic reviews2025
The association between smoking and diabetic neuropathy: a systematic review and meta-analysis.
Synthesis in Systematic reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe study aimed to systematically review the evidence on the association between smoking and the risk of diabetic neuropathy, with a particular emphasis on the risk of peripheral neuropathy among individuals with diabetes mellitus. DESIGN AND
methodsMEDLINE, EMBASE, SCOPUS, and CENTRAL databases were searched for studies published before August 2024. Cross-sectional, case-control, and cohort studies that assessed the association between smoking and diabetic neuropathy in individuals diagnosed with diabetes mellitus (type 1 or type 2), reported smoking as an exposure, and any type of diabetic neuropathy as an outcome were included in the study. The risk of bias of the included studies was evaluated using the modified risk of bias in non-randomized studies-of exposures (ROBINS-E).
resultsSeventy-five articles, including 228,699 individuals with diabetes met the inclusion criteria. Fifty-four cross-sectional, 8 case-control, and 13 cohort studies provided data for the meta-analyses. Cohort studies demonstrated a significantly increased risk of diabetic peripheral neuropathy (RR 1.28; 95% CI 1.05, 1.51), the most prevalent subtype of diabetic neuropathy. Meta-analyses of cross-sectional and case-control revealed an increased risk of diabetic neuropathy (all types combined) among smokers with diabetes ([OR 1.29; 95% CI 1.17, 1.41], [OR 1.48; 95% CI 1.23, 1.72]). Meta-regression showed no statistically significant impact of total sample size and type of effect estimates on pooled effect estimates for cross-sectional, case-control, and cohort studies.
conclusionSmoking is associated with an increased risk of diabetic neuropathy, peripheral neuropathy in particular. Future research should evaluate the precise dynamics of neuropathy pathogenesis among individuals with diabetes to prevent such complications. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022363380.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.